Wire · opportunities
Abbott launches SimpleScreen CRC blood test in the US
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 October 2026 · Fusion42 review
Abbott has launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for average-risk adults age 45 and older in the US, complementing its existing stool-based tests. The test offers an alternative for individuals unwilling or unable to undergo colonoscopy and is designed to increase screening rates and early detection.
This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 30 Sep 2026 and 2 Oct 2026.
◆ ◆ The Wire takeaway
You can now offer a less invasive colorectal cancer screening option that could win over patients avoiding colonoscopy. This launch opens a direct sales route for blood-based cancer detection beyond traditional stool tests.
◆ Coverage
4 sources · first reported 30 Sep 2026 · latest 2 Oct 2026
◆ Related on Wire
◆ Topics